Skip to main content
SpringerLink
Log in

Antihypertonika

  • Chapter
Arzneiverordnungs-Report 2004

  • 68 Accesses

Zusammenfassung

Als spezielle Antihypertonika werden in diesem Kapitel neben Atpharezepto-renblockern und zentral wirkenden Antisympathikotonika in erster Linie Kombinationspräparate von Betarezeptorenblockem, Calciumantagonisten und Reserpin dargestellt.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 49.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 79.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Anlauf M (1994): Hypertonie im Alter. MMV Medizin Verlag, München.

    Google Scholar 

  • Anlauf M, Hense HW (2003): Echte und vermeintliche Sparpotenziale in der Hochdrucktherapie — Neues aus dem Zauberhut. Dtsch Med Wschr 128:1557–1559.

    Article  PubMed  CAS  Google Scholar 

  • Anlauf M, Tholl U, Hirche H, Weber F (2001): A silent revolution in blood pressure measurement? Some late remarks in regards to the HOT study. J Hum Hypertension 15:649–651.

    Article  CAS  Google Scholar 

  • Anlauf M, Weber F (2004): Rauchen und Hypertonie (im Druck)

    Google Scholar 

  • Arzneimittelkommission der Deutschen Ärzteschaft (2004): Empfehlungen zur Therapie der arteriellen Hypertonie. 2. Auflage AVP.

    Google Scholar 

  • Attwood S, Bird R, Burch K, Casadei B, Coats A, Conway J, Dawes M, Ebbs D, Farmer A, Robinson J (1994): Within-patient correlation between the antihypertensive effects of atenolol, lisinopril and nifedipine. J Hypertens 12:1053–1060.

    Article  PubMed  CAS  Google Scholar 

  • Barmer Information (2003): Pressekonferenz der Barmer „Mehr Qualität statt weniger Leistung“, 23. April 2003.

    Google Scholar 

  • Berl T, Hunsicker LG, Lewis JB, Pfeffer MA et al (2003): Cardiovascular Outcomes in the Irbesartan Diabetic Nephropathy Trial of Patients with Type 2 Diabetes and Overt Nephropathy. Ann Intern Med 138: 542–549.

    PubMed  CAS  Google Scholar 

  • Black HR, Elliott WJ, Grandits G, Grambsch P, Lucente T, White WB et al for the CONVINCE Research Group (2003): Principal Results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) Trial. JAMA 289: 2073–2082.

    Article  PubMed  CAS  Google Scholar 

  • Bock KD, Anlauf M (1984): Die Qual der Wahl — das Dilemma der Hochdrucktherapie. Münch Med Wochenschr 16:477–479.

    Google Scholar 

  • Chobanian AV, Bakris GL, Black HR, Cushman WC et al (2003): The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA 289:2560–2571.

    Article  PubMed  CAS  Google Scholar 

  • Cohn JN, Pfeffer MA, Rouleau J, Sharpe N et al (2003): Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure. Eur J Heart Fail 5: 659–667

    Article  PubMed  CAS  Google Scholar 

  • Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR et al, ALLHAT Collaborative Research Group (2002): Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens 4: 393–404.

    Article  Google Scholar 

  • Deutsche Hochdruckliga (2003): Empfehlungen zur Therapie der arteriellen Hypertonie. Heidelberg

    Google Scholar 

  • Dickerson JEC, Hingorani AD, Ashby MJ, Palmer CR, Brown MJ (1999): Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet 353:2008–2013.

    Article  PubMed  CAS  Google Scholar 

  • Guidelines Committee (2003): 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 21:1011–1053.

    Article  Google Scholar 

  • Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D et al (1998): Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 351:1755–1762.

    Article  PubMed  CAS  Google Scholar 

  • Jackson PR, Ramsay LE (2002): The United States JNC VI and British Hypertension Society Guideline. The International WHO/ISH Guideline. First-line treatment for hypertension. Eur Heart J 23:179–182.

    Article  PubMed  CAS  Google Scholar 

  • Law MR, Wald NJ, Morris JK, Jordan RE (2003): Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 326:1427–1434

    Article  PubMed  CAS  Google Scholar 

  • Luft FC (2001): Recent clinical trial highlights in hypertension. Curr Hypertens Rep 3:133–138.

    Article  PubMed  CAS  Google Scholar 

  • Medical Research Council Working Party (1985): MRC trial of treatment of mild hypertension. Brit Med J 291: 97–104.

    Article  Google Scholar 

  • Messerli FH, Grossman E, Goldbourt U (1998): Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA 279:1903–1907.

    Article  PubMed  CAS  Google Scholar 

  • Middeke M, Anlauf M, Baumgart P, Franz A, Krönig B, Schrader J, Schulte KL (1998): Ambulante 24h-Blutdruckmessung. (ABDM). DMW 123:1426–1430.

    Google Scholar 

  • Neal B, MacMahon S, Chapman N for the Blood Pressure Lowering Treatment Trialists’ Collaboration (2000): Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 356:1955–1964.

    Article  PubMed  CAS  Google Scholar 

  • Neaton JD, Grimm RH, Prineas RJ, Stamler J, Grandits GA, for the Treatment of Mild Hypertension Study Research Group (1993): Treatment of Mild Hypertension Study Final Results. JAMA 270: 713–724.

    Article  PubMed  CAS  Google Scholar 

  • Pahor M, Psaty BM, Alderman MH, Applegate WB, Williamson JD, Cavazzini C, Furberg CD (2000): Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomised controlled trials. Lancet 356:1942–1943.

    Article  Google Scholar 

  • Piller LB, Davis BR, Cutler JA, Cushman WC, Wright JT Jr, Williamson JD et al (2002): Validation of heart failure events in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Participants Assigned to Doxazosin and Chlorthalidone. Curr Control Trials Cardiovasc Med 3:10.

    Article  PubMed  Google Scholar 

  • Pitt B, Byington RP, Furberg CD, Hunninghake DB, Mancini GB, Miller ME, Riley W for the PREVENT Investigators (2000): Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation 102: 1503–1510.

    Article  PubMed  CAS  Google Scholar 

  • PREMIER Collaborative Research Group (2003): Effects of comprehensive Lifestyle Modifikation on Blood Pressure Control. JAMA 289:2083–2093

    Article  Google Scholar 

  • Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, Weiss NS (2003): Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA 289:2534–2544.

    Article  PubMed  CAS  Google Scholar 

  • Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG et al (1997): Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 350: 757–764.

    Article  PubMed  CAS  Google Scholar 

  • Staessen JA, Gasowski J, Wang Lj G, Thijs L, et al (2000): Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 355: 865–872.

    Article  PubMed  CAS  Google Scholar 

  • The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2000): Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 283:1967–1975.

    Article  Google Scholar 

  • The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002): Major outcomes in hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288: 2981–2997.

    Article  Google Scholar 

  • Thijs L, Fagard R, Lijnen P, Staessen JA, Van Hoof R, Amery A (1992): A meta-analysis of outcome trials in elderly hypertensives. J Hypertension 10:1103–1109.

    Article  CAS  Google Scholar 

  • Weber MA, Julius S, Kjeldsen SE, Brunner HR (2004): Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 363: 2049–2054.

    Article  PubMed  CAS  Google Scholar 

  • Williams B, Poulter NR, Brown MJ, Davis M et al (2004), Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 18:139–185.

    Article  PubMed  CAS  Google Scholar 

  • Wing LMH, Reid MC, Ryan P, Beilin LJ et al for the Second Australian National Blood Pressure Study Group (2003): A comparison of outcomes with angioten-sin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 348: 583–592.

    Article  PubMed  CAS  Google Scholar 

  • Wolf-Maier K, Cooper RS, Banegas JR, Giampaoli S, Hense HW et al (2003): Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 289:2363–2369.

    Article  PubMed  Google Scholar 

  • Zanchetti A, Hansson L, Clement D, Elmfeldt D et al (2003): Benefits and risks of more intensive blood pressure lowering in hypertensive patients of the HOT study with different risk profiles: does a J-shaped curve exist in smokers? J Hypertens 21: 797–804.

    Article  PubMed  CAS  Google Scholar 

  • Zhu QM, Lesnick JD, Jasper JR, MacLennan SJ, Dillon MP, Eglen RM, Blue DR (1999): Cardiovascular effects of rilmenidine, moxonidine and Clonidine in conscious wild-type and D79N alpha2A-adrenoceptor transgenic mice. Br J Pharmacol 126:1522–1530.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Friedrich-Plettke-Weg 12, 27570, Bremerhaven

    Prof. Dr. med. Manfred Anlauf

Authors
  1. Prof. Dr. med. Manfred Anlauf
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pharmakologisches Institut der Universität Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg

    Ulrich Schwabe

  2. Bachstraße 29, 50858, Köln

    Dieter Paffrath

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Anlauf, M. (2004). Antihypertonika. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2004. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-18513-7_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-18513-7_15

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-21359-8

  • Online ISBN: 978-3-642-18513-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation